METOCLOPRAMIDE
Migraine Without Aura
Assistance Publique - Hôpitaux de ParisSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Migraine Without Aura cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topiramate Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 4 | BBB |
DHE Satsuma Pharmaceuticals, Inc. | Phase 3 | BBB |
Apsolol Norwegian University of Science and Technology | Phase 3 | BB |
Rimegepant University of South Florida | Phase 4 | BB |
DEXKETOPROFEN Kecioren Education and Training Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
METOCLOPRAMIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →